• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      New patent laws lure pharma MNCs to India

      Posted AtThe Economic Times

      India is increasingly becoming the darling of pharma MNCs, who are vying with each other to set up operations here. One of the main triggers for this growth is the change in the country's patent laws.

      Haruo Naito, president and CEO of Eisai, recently made his first trip to India. If anything, it's a clear sign that Japan's fourth largest pharmaceutical company has big plans for India. The company has just set up its operations in India and has already rolled out two products into the domestic market.

      "One factor that played a role in bringing Eisai to India is the passing of product patent law," says Deepak Naik, MD of Eisai Pharmaceuticals India. The other factor was that Eisai's early experience in the country gave a positive sign on the potential of the country.

      "We outlicensed our product, Methycobal, to Wockhardt a few years ago and that product created a market of Rs 150 crore," Mr Naik said. Two months ago, Eisai launched two more products -- Aricept and Parit (being marketed by GlaxoSmithKline) -- and both are doing "very well."

      What's more, Eisai is now looking at other options for taking advantage of India's growth. "We are doing the feasibility for other aspects of business," said Mr Naik. Some of the future investments could be in R&D and clinical trials.

      November 18, 2005


       

      Share this Article!

    Back to top^